Skip to main content
Fig. 6 | Alzheimer's Research & Therapy

Fig. 6

From: Serotonin augmentation therapy by escitalopram has minimal effects on amyloid-β levels in early-stage Alzheimer’s-like disease in mice

Fig. 6

Amyloid-β (Aβ) content in the brain of 5,7-dihydroxytryptamine (DHT)-lesioned APPSWE/PS1ΔE9 (APP/PS1) mice. a–f Aβ plaques formed in the neocortex (ad) and hippocampus (e, f) of sham-operated (a, c, e) and DHT-lesioned (b, d, f) APP/PS1 mice, as shown by shown by 6E10 IHC. Cortical layers are indicated by roman numerals. DG Dentate gyrus, g Granule cell layer, h Hilus, molecular layer. Scale bars = 50 μm (a, b, e, f), 100 μm (c, d). g–j Levels of insoluble (guanidine fraction) and soluble (PBS fraction) Aβ40 and Aβ42 in the neocortex (g, i) and hippocampus (h, j) of APP/PS1 after sham operation and DHT-induced lesioning were estimated by Meso Scale Discovery multiplex analysis. Data are presented as mean ± SEM

Back to article page